These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 1849164)

  • 1. Intermittent, alternating, and concurrent regimens of zidovudine and 2'-3' dideoxycytidine in the LP-BM5 murine induced immunodeficiency model.
    Basham T; Holdener T; Merigan T
    J Infect Dis; 1991 Apr; 163(4):869-72. PubMed ID: 1849164
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Salvage therapy for zidovudine-intolerant HIV-infected patients with alternating and intermittent regimens of zidovudine and dideoxycytidine.
    Bozzette SA; Richman DD
    Am J Med; 1990 May; 88(5B):24S-26S. PubMed ID: 2159706
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alternating and intermittent regimens of zidovudine (3'-azido-3'-deoxythymidine) and dideoxycytidine (2',3'-dideoxycytidine) in the treatment of patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex.
    Skowron G; Merigan TC
    Am J Med; 1990 May; 88(5B):20S-23S. PubMed ID: 2159705
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alternating and intermittent regimens of zidovudine and dideoxycytidine in patients with AIDS or AIDS-related complex.
    Skowron G; Bozzette SA; Lim L; Pettinelli CB; Schaumburg HH; Arezzo J; Fischl MA; Powderly WG; Gocke DJ; Richman DD; Pottage JC; Antoniskis D; McKinley GF; Hyslop NE; Ray G; Simon G; Reed N; LoFaro ML; Uttamchandani RB; Gelb LD; Sperber SJ; Murphy RL; Leedom JM; Grieco MH; Zachary J; Hirsch MS; Spector SA; Bigley J; Soo W; Merigan TC
    Ann Intern Med; 1993 Mar; 118(5):321-30. PubMed ID: 8094279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dideoxycytidine alone and in an alternating schedule with zidovudine in children with symptomatic human immunodeficiency virus infection.
    Pizzo PA; Butler K; Balis F; Brouwers E; Hawkins M; Eddy J; Einloth M; Falloon J; Husson R; Jarosinski P
    J Pediatr; 1990 Nov; 117(5):799-808. PubMed ID: 2172501
    [TBL] [Abstract][Full Text] [Related]  

  • 6. AIDS Clinical Trials Group: phase I/II study of combination 2',3'-dideoxycytidine and zidovudine in patients with acquired immunodeficiency syndrome (AIDS) and advanced AIDS-related complex.
    Meng TC; Fischl MA; Richman DD
    Am J Med; 1990 May; 88(5B):27S-30S. PubMed ID: 2159707
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Delta Coordinating Committee.
    Lancet; 1996 Aug; 348(9023):283-91. PubMed ID: 8709686
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human immunodeficiency virus inhibition is prolonged by 3'-azido-3'-deoxythymidine alternating with 2',3'-dideoxycytidine compared with 3'-azido-3'-deoxythymidine alone.
    Spector SA; Ripley D; Hsia K
    Antimicrob Agents Chemother; 1989 Jun; 33(6):920-3. PubMed ID: 2548440
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dideoxycytidine: current clinical experience and future prospects. A summary.
    Broder S; Yarchoan R
    Am J Med; 1990 May; 88(5B):31S-33S. PubMed ID: 2159708
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytomegalovirus retinitis under combination therapy with zidovudine and dideoxycytidine in advanced human immunodeficiency virus infection.
    Kaulen P; Pham DT; Baranowski E; Wollensak J
    Ger J Ophthalmol; 1993 Nov; 2(6):412-5. PubMed ID: 8312826
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Zidovudine (AZT) reduces virus titer, retards immune dysfunction, and prolongs survival in the LP-BM5 murine induced immunodeficiency model.
    Basham T; Rios CD; Holdener T; Merigan TC
    J Infect Dis; 1990 May; 161(5):1006-9. PubMed ID: 2157768
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination therapy with zidovudine and dideoxycytidine in patients with advanced human immunodeficiency virus infection. A phase I/II study.
    Meng TC; Fischl MA; Boota AM; Spector SA; Bennett D; Bassiakos Y; Lai SH; Wright B; Richman DD
    Ann Intern Med; 1992 Jan; 116(1):13-20. PubMed ID: 1345755
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Sequential dideoxycytidine and zidovudine in advanced HIV-1 infection. Phase II study].
    Ruiz-Argüelles GJ; Lagunes-Yannelli B; Mercado-Díaz L
    Rev Invest Clin; 1993; 45(2):145-7. PubMed ID: 8393211
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of 3'azidothymidine administered in drinking water or by continuous infusion on the development of MAIDS.
    Eiseman JL; Yetter RA; Fredrickson TN; Shapiro SG; MacAuley C; Bilello JA
    Antiviral Res; 1991 Dec; 16(4):307-26. PubMed ID: 1663732
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Resistance to AZT and ddC during long-term combination therapy in patients with advanced infection with human immunodeficiency virus.
    Richman DD; Meng TC; Spector SA; Fischl MA; Resnick L; Lai S
    J Acquir Immune Defic Syndr (1988); 1994 Feb; 7(2):135-8. PubMed ID: 7905522
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Studies of zidovudine in combination with didanosine and zalcitabine.
    Jablonowski H
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 1():S52-6. PubMed ID: 8595509
    [TBL] [Abstract][Full Text] [Related]  

  • 17. AZT studies reinforce benefits of combination.
    AIDS Alert; 1995 Jan; 10(1):11-2. PubMed ID: 11362167
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Major study shows AZT monotherapy inferior.
    James JS
    AIDS Treat News; 1995 Sep; (no 231):3-4. PubMed ID: 11362867
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of human immunodeficiency virus-infected infants and young children with dideoxynucleosides.
    Pizzo PA
    Am J Med; 1990 May; 88(5B):16S-19S. PubMed ID: 2159704
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 3'-Azido-3'-deoxythymidine prevents induction of murine acquired immunodeficiency syndrome in C57BL/10 mice infected with LP-BM5 murine leukemia viruses, a possible animal model for antiretroviral drug screening.
    Ohnota H; Okada Y; Ushijima H; Kitamura T; Komuro K; Mizuochi T
    Antimicrob Agents Chemother; 1990 Apr; 34(4):605-9. PubMed ID: 1693056
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.